Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjogren's syndrome
| Autor: | Frans G. M. Kroese, Hendrika Bootsma, Bouke P. C. Hazenberg, Gwenny M Verstappen, Rada V Moerman, Arjan Vissink, Martha S van Ginkel, Esther Mossel, Johan Bijzet, Jolien F. van Nimwegen, Suzanne Arends |
|---|---|
| Přispěvatelé: | Personalized Healthcare Technology (PHT), Translational Immunology Groningen (TRIGR) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Systemic disease PATHOGENESIS Gastroenterology 0302 clinical medicine rituximab hemic and lymphatic diseases Medicine Pharmacology (medical) Longitudinal Studies SYSTEMIC-LUPUS-ERYTHEMATOSUS Randomized Controlled Trials as Topic Free Immunoglobulin Light Chain MALT lymphoma Middle Aged LYMPHOID-TISSUE LYMPHOMA Peeling skin syndrome Treatment Outcome Sjogren's syndrome biomarker Female Rituximab MONOCLONAL GAMMOPATHY Nephelometry medicine.drug Adult musculoskeletal diseases medicine.medical_specialty abatacept lymphoma CONTROLLED-TRIAL plasma cells 03 medical and health sciences RHEUMATOID-FACTOR Rheumatology Monitoring Immunologic Internal medicine biologic therapies Humans Immunologic Factors Rheumatoid factor 030203 arthritis & rheumatology B cells business.industry immunoglobulin free light chain Abatacept RITUXIMAB TREATMENT Lymphoma B-Cell Marginal Zone medicine.disease stomatognathic diseases 030104 developmental biology MARKER B-CELL HYPERACTIVITY Immunoglobulin Light Chains business disease activity Biomarkers ABATACEPT TREATMENT |
| Zdroj: | Rheumatology, 57(10), 1812-1821. Oxford University Press |
| ISSN: | 1462-0324 |
| Popis: | Objectives. Serum immunoglobulin free light chains (FLCs) are frequently elevated in B-cell-mediated autoimmune diseases, including primary SS (pSS). The objective of this study was to assess if serum FLCs can contribute to classification, mucosa-associated lymphoid tissue (MALT) lymphoma detection, monitoring of disease activity and treatment response in pSS.Methods. Serum samples of 100 consecutive patients suspected of pSS were included. Forty-five patients fulfilled ACR-EULAR criteria for pSS. Additionally, samples of 17 pSS patients with MALT lymphoma and longitudinal samples of pSS patients treated with rituximab (n = 20), placebo (n = 10) or abatacept (n = 15) were included. Serum FLC kappa/FLC lambda. was measured by nephelometry or turbidimetry.Results. At diagnosis, FLC kappa and FLC lambda serum levels were significantly higher in pSS compared with non-SS sicca patients. The FLC kappa/FLC lambda ratio was abnormal in 11% of pSS patients. In established MALT-pSS patients, without recent rituximab treatment (n = 12), 50% had abnormal FLC kappa/FLC lambda ratios. FLC measurement had no additional value for pSS classification, compared with IgG and anti-SSA. FLC levels correlated significantly with systemic disease activity, assessed by EULAR SS Disease Activity Index (ESSDAI) and clinical ESSDAI, both cross-sectionally and longitudinally following treatment. Treatment with rituximab or abatacept significantly lowered FLC levels. FLCs show a large sensitivity to change and relative changes induced by treatment were higher compared with IgG.Conclusion. Serum FLCs are elevated in pSS, and abnormal FLC kappa/FLC lambda. ratios may be indicative for the presence of MALT lymhoma. FLC levels can be used as a biomarker for systemic disease activity and monitoring treatment responses. FLCs are sensitive to change and have more favorable kinetics than IgG. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|